Immutep Limited

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 06:53:40 03/07/2024 BST			5-day change	1st Jan Change
0.29 ^AUD	0.00%		-33.91%	-16.67%

06-27	ADRs End Flat; Alarum Technologies Climbs 26%	DJ
06-27	Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	MT

Prima Biomed Ltd. Reports Consolidated Cash Flow Results for the Second Quarter and Year to Date Ended December 31, 2015

January 07, 2016 at 06:55 pm

Prima Biomed Ltd. reported consolidated cash flow results for the second quarter and year to date ended December 31, 2015. For the quarter, the company reported net operating cash flows of AUD 1,624,000.

For the year to date, the company reported net operating cash flows of AUD 6,764,000.

Latest news about Immutep Limited

ADRs End Flat; Alarum Technologies Climbs 26%	06-27	DJ
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	06-27	MT
Baird Trims Immutep Price Target to $6 From $7, Maintains Outperform Rating	06-27	MT
Immutep Reports Positive Results in Drug Combination Trial for Head, Neck Cancer	06-27	MT
Immutep Gets Exclusive Rights to Develop, Commercialize New Anti-LAG-3 Small Molecules	06-25	MT
Immutep Signs Agreement with Cardiff University for Development Cancer Treatment	06-25	MT
Immutep Completes Nearly AU$11 Million Retail Entitlement Offer	06-24	MT
Immutep Completes Stock Offering	06-05	MT
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	06-03	MT
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	06-03	MT
Immutep Raising AU$100 Million for Phase Three Trial	06-03	MT
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	06-03	CI
Capital One Initiates Immutep at Overweight Rating With $10 Price Target	05-17	MT
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	05-15	MT
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	05-15	CI
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO	05-03	CI
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	05-02	CI
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	05-02	MT
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	04-30	CI
Canaccord Starts Immutep at Buy, Price Target is AU$1.00	04-30	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	04-25	CI
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	04-24	MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	04-24	CI
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761	04-18	CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial	04-18	MT

Chart Immutep Limited

Duration

Period

More charts

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.29 AUD

Average target price

0.942 AUD

Spread / Average Target

+224.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUTEP LIMITED	-16.67%	275M
MODERNA, INC.	+17.72%	44.87B
IQVIA HOLDINGS INC.	-10.33%	37.8B
LONZA GROUP AG	+37.55%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	31.32B
CELLTRION, INC.	-8.44%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.32B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.07B
MEDPACE HOLDINGS, INC.	+31.93%	12.5B
BIO-TECHNE CORPORATION	-7.67%	11.23B

Other Biotechnology & Medical Research